Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPEG-rhG-CSF preconditioning in older women with diminished ovarian reserve undergoing first IVF
ChiCTR2400093649Phase 4Not yet recruiting
- Sponsor
- Chongqing Health Center for Women and Children
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegfilgrastim in Diminished Ovarian Reserve (DOR) (3 arms), sponsored by Chongqing Health Center for Women and Children. Primary endpoint: Expression of apoptosis-related genes in granulosa cells. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on ChiCTR2400093649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093649.